Clinical context
Cataract surgery outcomes are not defined by best-corrected visual acuity alone. Refractive accuracy, vision at different distances, spectacle dependence, contrast sensitivity, dysphotopsia and procedural safety all matter. Corneal and macular status, capsular support, cataract density and IOL calculation also shape the final result. A statistically convincing average therefore still has to be interpreted against the characteristics of an individual eye.
What was studied
The authors compared IOL formula accuracy in patients with axial length below 22 mm. PubMed, Embase, Web of Science and the Cochrane Library were searched for studies published from January 2003 through September 2023. The network meta-analysis included 15 prospective or retrospective clinical studies, 1,178 eyes and 12 formulas; outcomes covered absolute error and the proportions within ±0.25, ±0.50 and ±1.00 D.
How the evidence was produced
A meta-analysis combines several studies and can increase the precision of an overall estimate. Its conclusion still depends on the quality of the component studies, comparability of interventions and endpoints, statistical heterogeneity and publication bias. The pooled effect should be read with its confidence interval, sensitivity analyses and the reasons results differed across studies.
How to interpret the result
In a short eye, a small error in predicted effective lens position can produce a meaningful refractive miss because the implanted lens has high optical power. The ranking supports Kane, Haigis and Olsen Standalone as reasonable formulas to examine during planning. Yet Kane did not differ significantly from Haigis for the proportions within the target ranges, so a rank table should not become a universal instruction to use one formula.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
This evidence is most useful as a basis for preoperative discussion and surgical planning. It helps identify which outcomes should be measured and which trade-offs should be explained to patients. The average effect should not be generalized to every IOL, technique or patient without checking eligibility criteria, surgeon experience, biometry, ocular comorbidity and duration of follow-up.
Limitations
The network combines observational studies using different biometers, IOL models, constant-optimization methods and definitions of a short eye. SUCRA estimates ranking probability rather than the size of a guaranteed clinical advantage. The search ended in 2023, so newer formula versions may be incompletely represented. The authors call for large multicenter registry studies.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.